BioCentury on BioBusiness,
Tools & Techniques
Cor's new anti-platelet play
Tuesday, January 16, 2001
In the search for better oral anti-platelet drugs, oral platelet
inhibition based on GPIIb/IIIa antagonists has proven to be more difficult than expected.
Cor Therapeutics Inc. is one of the few remaining companies with an oral GPIIb/IIIa
inhibitor, Cromafiban, in development for acute coronary syndrome or cerebrovascular
accidents. But it also is hedging its bets with another mediator of platelet aggregation,
Last week, CORR published in Nature the cloning of P2Y12, a
platelet ADP-receptor. The company's investment in P2Y12 provides it with a new target for
development of an oral platelet inhibitor
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]